CLSD

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Clearside Biomedical (CLSD - Research Report), with a price target of $7.00. The company's shares opened today at $1.30.According to TipRanks, Wolleben is an analyst with an average return of -14.2% and a 27.15% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Madrigal Pharmaceuticals, and Clearside Biomedical.Clearside Biomedical has an analyst consensus of Strong Buy, with a price target consensus of $7.00.See the top stocks recommended by analysts >>The company has a one-year high of $5.22 and a one-year low of $1.00.
https://www.tipranks.com/news/blurbs/clearside-biomedical-clsd-gets-a-buy-from-jmp-securities?utm_source=advfn.com&utm_medium=referral